Solid tumors have proven stubbornly resistant to CAR T cell immunotherapy, which has revolutionized blood cancers but struggles against the protective fortress that solid tumors build around themselves. This resistance stems from tumor cells' ability to recruit supportive stromal cells that create an immunosuppressive shield, making traditional single-target approaches ineffective.
Investigators have now identified urokinase plasminogen activator receptor (uPAR) as a master target that appears across multiple solid tumor types, particularly those harboring TP53 and RAS mutations—the most common cancer drivers. CAR T cells engineered to recognize uPAR demonstrated remarkable efficacy, simultaneously attacking both tumor cells and their protective stromal support network. In preclinical models spanning diverse cancer types, these uPAR-directed CAR T cells achieved complete tumor elimination, eradicated distant metastases, and maintained their killing power when combined with senescence-inducing treatments.
This represents a potential paradigm shift in cancer immunotherapy strategy. Rather than hunting individual tumor antigens that vary between patients, targeting uPAR exploits a convergent vulnerability where tumors essentially paint targets on both themselves and their support systems. The approach addresses solid tumor immunotherapy's two fundamental challenges: antigen diversity and stromal protection. While CAR T therapy has struggled to translate beyond blood cancers for over a decade, uPAR targeting offers a unifying mechanism that could finally crack the solid tumor code. However, the leap from promising mouse models to human efficacy remains the critical test, as many immunotherapy approaches have stumbled at this transition despite compelling preclinical data.